http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
-
Legend Biotech (LEGN) Announces CARVYKTI Receives Recommendation from FDA Committee for Earlier Treatment of Patients with R/R Multiple Myeloma
-
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
-
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
-
Legend Biotech (LEGN) Announces Positive CHMP Opinion for CARVYKTI for Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
-
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of T
-
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Legend Biotech (LEGN) Announces Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symp
-
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CA
-
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
-
Legend Biotech (LEGN) Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
-
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
-
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
-
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
-
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
-
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
-
Legend Biotech (LEGN) Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI
-
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
-
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
-
Legend Biotech Announces Participation in Upcoming Investor Conferences
-
Legend Biotech (LEGN) Announces Submission to EMA for Expanded Use of CARVYKTI
-
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
-
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
-
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
-
Legend Biotech Announces Participation in Upcoming Investor Conference
-
Exelixis Advances Board Refreshment Plan
-
Legend Biotech (LEGN) Appoints Mythili Koneru as Chief Medical Officer
-
Legend Biotech Announces Appointment of Chief Medical Officer
-
Legend Biotech (LEGN) Establishes Strategic Advisory Board
-
Legend Biotech Establishes Strategic Advisory Board
-
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
-
Legend Biotech Announces Participation in Upcoming Investor Conferences
-
Legend Biotech (LEGN) Regains Nasdaq Compliance
-
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
-
Legend Biotech (LEGN) Announces Phase 3 CARTITUDE-4 Study of CARVYKTI Met Its Primary Endpoint
-
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
-
Legend Biotech (LEGN) Announces Notification of Delinquency from The Nasdaq Stock Market
-
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC
-
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
-
Legend Biotech (LEGN) Announces Acceptance of NDA for Ciltacabtagene Autoleucel in China
-
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
-
Legend Biotech (LEGN) Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
-
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
-
Legend Biotech Announces Participation in Upcoming Investor Conferences
-
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
-
Legend Biotech (LEGN) Announces CARVYKTI Approved in Japan for Treatment of Relapsed or Refractory Multiple Myeloma
